Advertisement
Canada markets close in 2 hours 15 minutes

  • S&P/TSX

    21,687.51
    -52.69 (-0.24%)
     

  • S&P 500

    5,060.07
    -1.75 (-0.03%)
     

  • DOW

    37,862.26
    +127.15 (+0.34%)
     

  • CAD/USD

    0.7236
    -0.0017 (-0.24%)
     

  • CRUDE OIL

    85.21
    -0.20 (-0.23%)
     

  • Bitcoin CAD

    86,933.79
    -1,287.73 (-1.46%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,404.10
    +21.10 (+0.89%)
     

  • RUSSELL 2000

    1,967.33
    -8.37 (-0.42%)
     

  • 10-Yr Bond

    4.6860
    +0.0580 (+1.25%)
     

  • NASDAQ

    15,891.28
    +6.26 (+0.04%)
     

  • VOLATILITY

    18.75
    -0.48 (-2.52%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6810
    -0.0014 (-0.21%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AS COMPANY EARNINGS ROLL IN

Shares of Live Nation, parent company of Ticketmaster, fall on antitrust probe report

Analysis Reports On Active NASDAQ Stocks: (NASDAQ: ATHX), (NASDAQ: PDLI)

ACCESSWIRE

New York (April 18th, 2013) - Athersys, Inc. (NASDAQ:ATHX - News) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Athersys' application to expand its ongoing Phase 2 study evaluating the administration of MultiStem(R) therapy to patients who have suffered an ischemic stroke. Enrollment at United Kingdom sites is expected to commence following final Ethics Committee review and the completion of final preparations at participating clinical centers.

"The MHRA authorization will enable us to bring several leading United Kingdom stroke centers into the study, which will help us to speed the completion of the stroke clinical trial," said Dr. Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys. "The authorization is also noteworthy as it marks the initiation of MultiStem clinical development activity in the United Kingdom."

Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine.

Get everything traders and investors are looking for when trading ATHX here:

ADVERTISEMENT

http://stockreportdaily.com/market-scan/?symbol=ATHX


PDL BioPharma Inc. (NASDAQ:PDLI - News) traded at $ 7.45 in the last session, which is 0.00 (0.00%). The stock has a Range of 7.31 - 7.46. The stock has a 52 week low and high of 6.09 - 8.43 respectively. The stock has a Market Cap of 1.04B. The stock traded a volume of 1.66M. The stock has a 30 day average volume of 1.81M.

In trading on Wednesday, shares of PDL BioPharmaInc (PDLI) crossed below their 200 day moving average of $7.32, changing hands as low as $7.31 per share.

PDL BioPharma, Inc. (PDL) is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014.

Find out more on PDLI here:

http://stockreportdaily.com/market-scan/?symbol=PDLI

ABOUT US:

Stockreportdaily.com issues momentum alerts on stocks that can provide gains to day traders. Stockreportdaily.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. Stockreportdaily.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Stockreportdaily.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Stockreportdaily.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www. Stockreportdaily.com

Disclosure: Stockreportdaily.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Stockreportdaily.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.Stockreportdaily.com/disclaimer/

Contact Info:
George Fitz
Stock Report Daily
info@Stockreportdaily.com
347-905-5009